Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 15, 2021, Corvus Pharmaceuticals, Inc. (the "Company") held its 2021
Annual Meeting of Stockholders (the "Annual Meeting"). Only stockholders of
record at the close of business on April 19, 2021, the record date for the
Annual Meeting, were entitled to vote at the Annual Meeting. As of the record
date, there were 38,309,551 shares of the Company's common stock outstanding and
entitled to vote at the Annual Meeting. At the Annual Meeting, 27,719,139 shares
of the Company's common stock were voted in person or by proxy for the two
proposals set forth below, each of which is described in the Company's
Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and
Exchange Commission on April 20, 2021.
The tabulation of the stockholder votes on each proposal brought before the
Annual Meeting is as follows:
Proposal No. 1 - Election of Directors
The Company's stockholders elected the Class II director nominees below to the
Company's Board of Directors to hold office until the 2024 Annual Meeting of
Stockholders or until their respective successors are elected and qualified or
appointed, or the earlier of their death, resignation or removal.
Class II Director Nominees Votes For Votes Withheld Broker Non-Votes
Scott W. Morrison 20,548,120 169,572 7,001,447
Edith P. Mitchell, M.D. 20,572,477 145,215 7,001,447
Proposal No. 2 - Ratification of Selection of Independent Registered Accounting
The Company's stockholders ratified the selection of PricewaterhouseCoopers LLC
as the independent registered public accounting firm of the Company for its
fiscal year ending December 31, 2021.
Votes For Votes Against Abstain
27,550,167 47,149 121,823
© Edgar Online, source Glimpses